CDKN2A and lung carcinoma: In another Chinese case-control study, it was reported that there were statistically significant differences in the promoter methylation levels of p16 (CDKN2A, cyclin dependent kinase inhibitor 2A), RASSF1A (Ras association domain family member 1A), and FHIT (fragile histidine triad) between lung cancer cases and controls.